ClinicalTrials.gg
TerminatedNCT02120417Updated Feb 13, 2018Results posted

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

A Phase 2 interventional study of Ruxolitinib and Capecitabine in Breast Cancer, sponsored by Incyte Corporation. Terminated at 107 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Breast Neoplasms by Incyte Corporation — none open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Incyte Corporation.

Enrollment
4th of 10
149 · median 103
Started
2014
the only one that year
Phase 2
2 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Breast Neoplasms by Incyte Corporation, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 10 studies in Breast Neoplasms by Incyte Corporation is open now. The open studies under Breast Neoplasms, anywhere →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Breast Neoplasms by Incyte Corporation as a file.
02

Study summary

This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in combination with ruxolitinib versus those who received treatment with capecitabine alone.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed -negative adenocarcinoma of the breast
  • Locally advanced (Stage 3B) or (Stage 4) disease
  • (ECOG) performance status 0 to 2
  • Received up to 2 prior chemotherapy regimens (not including /adjuvant therapy) for advanced or metastatic disease
  • Participants with hormone-receptor positive tumors must have failed available lines of hormonal therapy unless hormone therapy was not tolerated or not clinically appropriate
  • ≥ 2 weeks elapsed from the completion of previous treatment regimen and must have recovered or be at a new stable baseline from any related toxicities
  • Radiographically measurable or evaluable disease
  • An mGPS of 1 or 2 as defined below:

    • Criteria:

      1. modified Glasgow prognostic score (mGPS) of 1: CRP > 10 mg/L and albumin ≥ 35 g/L
      2. mGPS of 2: C-reactive protein (CRP) > 10 mg/L and albumin \< 35 g/L

Exclusion criteria

Exclusion Criteria:

  • Received prior treatment with capecitabine or fluoropyrimidine for advanced or disease
  • Received more than 2 prior regimens for advanced or metastatic disease (not including hormonal therapy in the metastatic setting or or adjuvant therapies)
  • Unknown hormone-receptor status
  • Ongoing radiation therapy or radiation therapy administered within 2 weeks of enrollment
  • Concurrent anticancer therapy
  • Inadequate renal, hepatic or bone marrow function
  • Another current or previous within 2 years of study entry unless approved by the sponsor
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Treatment A - Capecitabine and ruxolitinib

    Drug: Ruxolitinib · Drug: Capecitabine

  • Active comparator
    Treatment B - Capecitabine and placebo

    Drug: Capecitabine · Drug: Placebo

Interventions

  • 5 mg tablets to be administered by mouth Ruxolitinib 15 mg BID (starting dose)

    Also known as: Jakafi ®, Jakavi ®

  • Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle

  • DrugPlacebo

    5 mg matching placebo tablets to be administered by mouth

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is reported here by the number of days from randomization to death until the data cutoff for the final analysis. The hazard ratio (80% CI) for ruxolitinib versus placebo was estimated using a Cox regression model stratified by hormone-receptor status.

    Time frame: Randomization until death due to any cause up to 19 months or the data cutoff 08FEB2016.

  2. Median Survival

    Survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.

    Time frame: Randomization until death due to any cause up to 19 months or the data cutoff 08FEB2016.

  3. Percentage of Participants Achieving Overall Survival

    Overall survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.

    Time frame: Randomization until death due to any cause at month 3, 6, 9, 12 and 15 or the data cutoff 08FEB2016.

Secondary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival was defined as the time from the randomization date to the earliest date of disease progression, as measured by investigator assessment of objective radiographic disease assessments per RECIST (v1.1), or death from any cause if earlier. Progression-free survival time distribution and median survival for each treatment group were analyzed using the Kaplan-Meier method.

    Time frame: Randomization to disease progression, or death due to any cause if sooner up to 19 months or the data cutoff 08FEB2016.

  2. Percentage of Participants Achieving Objective Response Rate

    Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

    Time frame: Randomization through end of study up to 19 months or the data cutoff 08FEB2016.

  3. Duration of Response (DOR)

    The DOR was defined as the difference (in number of months) between the end of response and the start of response for participants who had at least 1 response measurement. The start of a response was the first visit where the participant achieved a partial response or better based on RECIST (v1.1) criteria. The end of response was the earlier of death or progressive disease based on RECIST (v1.1) criteria. The date of progressive disease was the date on which progression was first recorded. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

    Time frame: Randomization through end of study up to 19 months or the data cutoff 08FEB2016.

  4. Percentage of Participants Achieving Clinical Benefit Rate

    Clinical benefit rate was defined as a complete response, partial response, or stable disease, determined by investigator assessment of objective radiographic disease assessments per RECIST (v1.1) that lasted for ≥ 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

    Time frame: Randomization through end of study up to 19 months or the data cutoff 08FEB2016.

07

Results

Posted Jul 12, 2017

Participant flow

This study was conducted at 72 study centers (65 in the United States and 7 in the European Union \[3 in the United Kingdom, 3 in Spain, and 1 in Portugal\]).

Participant flow — Overall Study
MilestoneTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Started7673
Completed165
Not completed6068
Withdrew: Death51
Withdrew: Adverse event39
Withdrew: Participant decision44
Withdrew: Disease progression4145
Withdrew: Noncompliance with study treatment02
Withdrew: Physician decision23
Withdrew: Other unspecified54

Outcome measures

PrimaryOverall Survival (OS)

Overall survival is reported here by the number of days from randomization to death until the data cutoff for the final analysis. The hazard ratio (80% CI) for ruxolitinib versus placebo was estimated using a Cox regression model stratified by hormone-receptor status.

Time frame:
Randomization until death due to any cause up to 19 months or the data cutoff 08FEB2016.
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Death events3938
Censored events3735
Statistical analysis
  • Treatment A - Capecitabine and Ruxolitinib vs Treatment B - Capecitabine and Placebo · Log Rank · p = 0.762 · Hazard ratio (hr): 0.932 · 80% CI 0.694 to 1.252The P-value was analyzed by Log-Rank Test stratified by Hormone Receptor Status.
PrimaryMedian Survival

Survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.

Time frame:
Randomization until death due to any cause up to 19 months or the data cutoff 08FEB2016.
Reported as:
Median · months
Median Survival
monthsTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Median Survival11.2 (7.5 to 12.7)10.9 (6.0 to 13.1)
SecondaryProgression-free Survival (PFS)

Progression-free survival was defined as the time from the randomization date to the earliest date of disease progression, as measured by investigator assessment of objective radiographic disease assessments per RECIST (v1.1), or death from any cause if earlier. Progression-free survival time distribution and median survival for each treatment group were analyzed using the Kaplan-Meier method.

Time frame:
Randomization to disease progression, or death due to any cause if sooner up to 19 months or the data cutoff 08FEB2016.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Progression-free Survival (PFS)4.5 (2.3 to 6.1)2.5 (2.1 to 4.1)
SecondaryPercentage of Participants Achieving Objective Response Rate

Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

Time frame:
Randomization through end of study up to 19 months or the data cutoff 08FEB2016.
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Objective Response Rate
percentage of participantsTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Complete Response rate0.00.0
Partial Response rate28.913.7
SecondaryDuration of Response (DOR)

The DOR was defined as the difference (in number of months) between the end of response and the start of response for participants who had at least 1 response measurement. The start of a response was the first visit where the participant achieved a partial response or better based on RECIST (v1.1) criteria. The end of response was the earlier of death or progressive disease based on RECIST (v1.1) criteria. The date of progressive disease was the date on which progression was first recorded. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

Time frame:
Randomization through end of study up to 19 months or the data cutoff 08FEB2016.
Reported as:
Median · months
Duration of Response (DOR)
monthsTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Duration of Response (DOR)4.2 (3.5 to 4.6)4.4 (3.8 to 6.4)
SecondaryPercentage of Participants Achieving Clinical Benefit Rate

Clinical benefit rate was defined as a complete response, partial response, or stable disease, determined by investigator assessment of objective radiographic disease assessments per RECIST (v1.1) that lasted for ≥ 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.

Time frame:
Randomization through end of study up to 19 months or the data cutoff 08FEB2016.
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Benefit Rate
percentage of participantsTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Percentage of Participants Achieving Clinical Benefit Rate13.26.8
PrimaryPercentage of Participants Achieving Overall Survival

Overall survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.

Time frame:
Randomization until death due to any cause at month 3, 6, 9, 12 and 15 or the data cutoff 08FEB2016.
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Overall Survival
percentage of participantsTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Month 3 Survival Rate0.855 (0.753 to 0.917)0.750 (0.633 to 0.835)
Month 6 Survival Rate0.674 (0.554 to 0.769)0.635 (0.511 to 0.735)
Month 9 Survival Rate0.537 (0.404 to 0.652)0.546 (0.417 to 0.657)
Month 12 Survival Rate0.435 (0.289 to 0.573)0.427 (0.286 to 0.561)
Month 15 Survival Rate0.319 (0.174 to 0.475)0.294 (0.148 to 0.456)

Adverse events

Collected over Participants received study treatment in continuous 21-day cycles until they met withdrawal criteria up to 19 months or the data cutoff 08FEB2016. The cutoff date of 08Feb2016 was chosen based on the date that the sponsor became aware that the seventieth death had occurred in the randomized population.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A - Capecitabine and Ruxolitinib—28/71 (39.4%)69/71 (97.2%)
Treatment B - Capecitabine and Placebo—29/71 (40.8%)69/71 (97.2%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
Pleural effusionRespiratory, thoracic and mediastinal disorders3/716/71
NauseaGastrointestinal disorders5/711/71
VomitingGastrointestinal disorders4/714/71
DyspnoeaRespiratory, thoracic and mediastinal disorders3/714/71
PneumoniaInfections and infestations3/711/71
DehydrationMetabolism and nutrition disorders3/711/71
Deep vein thrombosisVascular disorders0/713/71
NeutropeniaBlood and lymphatic system disorders2/710/71
Abdominal painGastrointestinal disorders2/711/71
AscitesGastrointestinal disorders0/712/71
Most frequent other events
Showing 10 of 60
Most frequent other events
EventTreatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and Placebo
FatigueGeneral disorders40/7131/71
NauseaGastrointestinal disorders39/7135/71
AnaemiaBlood and lymphatic system disorders35/7118/71
DiarrhoeaGastrointestinal disorders33/7119/71
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders33/7127/71
VomitingGastrointestinal disorders26/7119/71
DyspnoeaRespiratory, thoracic and mediastinal disorders22/7120/71
Decreased appetiteMetabolism and nutrition disorders21/7119/71
StomatitisGastrointestinal disorders19/7112/71
ConstipationGastrointestinal disorders18/7117/71

Baseline characteristics

The Intent-to-Treat (ITT) population consisted of all participants randomized to the study.

Age, Continuous
Age, Continuous(years)Treatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and PlaceboTotal
Mean54.3 ± 11.0055.0 ± 12.7554.6 ± 11.85
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A - Capecitabine and RuxolitinibTreatment B - Capecitabine and PlaceboTotal
Female7673149
Male000
08

Study locations

107 sites
  • Birmingham, Alabama, United States
  • Chandler, Arizona, United States
  • Sedona, Arizona, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Oxnard, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Santa Monica, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • New Haven, Connecticut, United States
  • Washington, District of Columbia, United States
  • Fort Myers, Florida, United States
  • Hialeah, Florida, United States
  • Miami, Florida, United States
  • Plantation, Florida, United States
  • Saint Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Savannah, Georgia, United States
  • Chicago, Illinois, United States
  • Quincy, Illinois, United States
  • Springfield, Illinois, United States
  • Urbana, Illinois, United States
  • Ames, Iowa, United States
  • Wichita, Kansas, United States
  • Louisville, Kentucky, United States
  • Baton Rouge, Louisiana, United States
  • Baltimore, Maryland, United States
  • Detroit, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Duluth, Minnesota, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Grand Island, Nebraska, United States
  • Omaha, Nebraska, United States
  • Camden, New Jersey, United States
  • Hackensack, New Jersey, United States
  • Farmington, New Mexico, United States
  • Albany, New York, United States
  • Bronx, New York, United States
  • Johnson City, New York, United States
  • New York, New York, United States
  • Goldsboro, North Carolina, United States
  • Pinehurst, North Carolina, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Middletown, Ohio, United States
  • Portland, Oregon, United States
  • Bethlehem, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Greenville, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Germantown, Tennessee, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • Bedford, Texas, United States
  • Dallas, Texas, United States
  • El Paso, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • McAllen, Texas, United States
  • Plano, Texas, United States
  • Tyler, Texas, United States
  • Ogden, Utah, United States
  • Salt Lake City, Utah, United States
  • Fairfax, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Salem, Virginia, United States
  • Seattle, Washington, United States
  • Green Bay, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
  • La Roche Sur Yon, France
  • Paris Cedex 10, France
  • Paris, France
  • Alba, Italy
  • Fano, Italy
  • Foggia, Italy
  • Lecco, Italy
  • Milano, Italy
  • Naples, Italy
  • Pontedera, Italy
  • Roma, Italy
  • Saronno, Italy
  • Lisbon, Portugal
  • A Coruña, Spain
  • Barcelona, Spain
  • Jaén, Spain
  • Lleida, Spain
  • Madrid, Spain
  • Cardiff, United Kingdom
  • Glasgow, United Kingdom

Showing the first 100 of 107 sites across 6 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Feb 2016, 21 months.

Results were first posted in Jul 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2014
First posted
Apr 22, 2014
StartActual
May 2014
Primary completionActual
Feb 2016
CompletionActual
Jan 2017
Results first posted
Jul 12, 2017
Last update
Feb 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02120417
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 22, 2014
Start date
May 2014
Primary completion
Feb 2016
Completion
Jan 2017
Results posted
Jul 12, 2017
Last update
Feb 13, 2018

Study contacts

Gerard Kennealey, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion